The 5 most recent market catalysts affecting $SCTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 92
Scribe Therapeutics Q3 EPS $(2.62) Misses $(1.05) Estimate, Sales $1.918M Miss $3.113M Estimate
Scribe Therapeutics (SCTX) announced Q3 earnings per share of $(2.62), missing the analyst consensus of $(1.05) by a substantial 149.52%. Concurrently, the company reported sales o…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 65
HC Wainwright & Co. Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $60
HC Wainwright & Co. initiating coverage on Scribe Therapeutics with a 'Buy' rating and a $60 price target is a positive development for the company. Analyst coverage, especially wi…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 65
Wells Fargo Initiates Coverage On Scribe Therapeutics with Overweight Rating, Announces Price Target of $60
Wells Fargo analyst Yanan Zhu has initiated coverage on Scribe Therapeutics (SCTX) with an 'Overweight' rating and a $60 price target. This event is significant as new analyst cove…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Initiates Coverage On Scribe Therapeutics with Outperform Rating, Announces Price Target of $37
Leerink Partners' analyst David Risinger has initiated coverage on Scribe Therapeutics (SCTX) with an 'Outperform' rating and a $37 price target. This event is significant as it ma…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 65
Guggenheim Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $50
Guggenheim analyst Debjit Chattopadhyay has initiated coverage on Scribe Therapeutics (SCTX) with a 'Buy' rating and a $50 price target. This event is significant as new analyst co…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.